Immunogenic compositions for the prevention and treatment of meningococcal disease
The present invention relates to Neisseria ORF2086 proteins, crossreactive immunogenic proteins which can be isolated from nesserial strains or prepared recombinantly, including immunogenic portions thereof, biological equivalents thereof, antibodies that immunospecifically bind to the foregoing and nucleic acid sequences encoding each of the foregoing, as well as the use of same in immunogenic compositions that are effective against infection by Neisseria meningitidis serogroup B.
1. A method of inducing a serum bactericidal antibody response against serogroup B Neisseria meningitidis subfamily B strains in a mammal comprising administering to said mammal a composition comprising an immunologically effective amount of a purified polypeptide consisting of the amino acid sequence of SEQ ID NO: 186.
2. The method of claim 1 , wherein the polypeptide is expressed as a fusion protein.
3. The method of claim 2 , wherein the fusion protein comprises a T7 tag sequence fused to the amino terminus of the purified polypeptide.
4. The method of claim 1 , wherein the polypeptide is non-lipidated.
5. The method of claim 1 , wherein the immunologically effective amount is 25 micrograms.
6. The method of claim 1 , wherein the composition further comprises QS-21.
7. The method of claim 1 , wherein the composition further comprises a pharmaceutically acceptable buffer, diluent, carrier, or adjuvant.
8. The method of claim 1 , wherein the composition further comprises aluminum hydroxide or aluminum phosphate.
9. The method of claim 1 , wherein the composition further comprises other Neisseria species immunogenic polypeptides.
10. The method of claim 1 , wherein the mammal is a human.
11. The method of claim 1 , wherein the composition further comprises a polysaccharide.